| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 819201 | 25 ug | $245 | ||
| 819202 | 100 ug | $595 |
| Application | FC |
|---|---|
| Format | Liquid, PE |
| Expression Host | CHO |
| Target Name | TNFRSF4, OX40, CD134, OX40L receptor |
| Species | Cynomolgus monkey |
| Sources | Recombinant Cynomolgus Monkey OX40 (Lue29-Ala216) with C-terminus Fc-tag is expressed in CHO cell and conjugated to PE. |
| Accession Number | A0A7N9CLL2 |
| Molecular Weight | The protein has a predicted molecular weight of 46.3 kDa. Under DTT-reducing conditions, it migrates at approximately 60 kDa on SDS-PAGE prior to conjugation. |
| Affinity Tag | C-Fc |
| Regulatory Status | RUO |
| Formulation | 1xPBS buffer, pH7.4, 0.09% NaN3 with a carrier protein |
| Endotoxin level | Not tested |
| Protein Concentration | 25µg size is bottled at 0.1mg/mL concentration. 100 µg size is bottled at lot specific concentration. |
| Storage and Handling | Briefly centrifuge the vial upon receipt. An unopened vial may be stored at 2–8°C for up to six months. |
OX40 (CD134) and its ligand OX40L (CD252), both part of the TNF receptor superfamily, play a key role in immune regulation. Their interaction is essential for T-cell expansion, survival, and cytokine production, influencing T cells, antigen-presenting cells, NK cells, and NKT cells. OX40-OX40L signaling helps break immune tolerance in malignancies, promoting antitumor immunity, and is also involved in the development of inflammatory and autoimmune diseases. Due to these regulatory effects, the OX40-OX40L pathway is a promising target for therapeutic interventions in both cancer and infectious diseases, with OX40 stimulation showing potential for therapeutic immunization strategies.
PE conjugated Cynomolgus Monkey OX40 (C-Fc) TDS
Have a product or application question? Consult our FAQs or contact us.
